# AstraZeneca’s Forxiga approved in Japan for CKD

- Link: https://www.directorstalkinterviews.com/astrazenecas-forxiga-approved-in-japan-for-ckd/4121019180
- Published: 2021-08-26T07:20:12+01:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
_Forxiga_ (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has
been approved in Japan for the treatment of chronic kidney disease (CKD) in adults
with and without type-2 diabetes (T2D).

The approval by Japan’s Ministry of Health, Labour and Welfare (MHLW) is based on
positive results from the DAPA-CKD Phase III trial.^(1) The decision follows the
Priority Review designation granted by the MHLW earlier this year.

CKD is a serious, progressive condition defined by decreased kidney function and
is often associated with an increased risk of heart disease or stroke.^(2-4) The
condition affects 840 million people worldwide.^(5) However, diagnosis rates remain
low and up to 90% of patients are unaware they have the disease.^(4) _Forxiga_ is
the first ever approved medicine for the treatment of the disease in Japan.^(6,7)

> **The national coordinator of the DAPA-CKD Phase III trial in Japan, Naoki Kashihara,
> President of the Japanese Society of Nephrology, said**: “DAPA-CKD is the landmark
> trial that demonstrated unprecedented risk reduction for chronic kidney disease
> patients with and without type-2 diabetes. This transformational milestone will
> bring great hope to many patients with chronic kidney disease in Japan.”

The DAPA-CKD Phase III trial demonstrated that _Forxiga_, on top of standard-of-
care (SoC) treatment with an angiotensin-converting enzyme inhibitor or an angiotensin
receptor blocker, reduced the relative risk of worsening of renal function, onset
of end-stage kidney disease (ESKD), or risk of cardiovascular (CV) or renal death
by 39%, the primary composite endpoint, compared to placebo (absolute risk reduction[
ARR]=5.3%, p<0.0001) in patients with CKD Stages 2-4 and elevated urinary albumin
excretion. _Forxiga_ also significantly reduced the relative risk of death from 
any cause by 31% (ARR=2.1%, p=0.0035) compared to placebo.^(8) The safety and tolerability
of _Forxiga_ were consistent with the well-established safety profile of the medicine.

_Forxiga_ (known as _Farxiga_ in the US) was recently approved in the US and the
European Union for the treatment of CKD in adults with and without T2D and is currently
under review in several other countries around the world. _Forxiga _is indicated
as an adjunct to diet and exercise to improve glycaemic control in adults with T2D
and as an oral adjunct treatment to insulin for adults with type-1 diabetes (T1D).
It is also approved for the treatment of symptomatic chronic heart failure (HF) 
with reduced ejection fraction (HFrEF) in adults with and without T2D. 

In 2013, AstraZeneca K.K. (AZKK), a subsidiary in Japan of AstraZeneca, entered 
into an agreement with Ono Pharmaceutical Co., Ltd. (Ono) for _Forxiga_. Based on
this agreement, Ono is responsible for distribution and marketing of _Forxiga_ in
Japan and has been co-promoting it with AZKK for the treatment of T2D, T1D and chronic
HF. Both Companies will co-promote for the treatment of CKD. 

**CKD** 

CKD is a serious, progressive condition defined by decreased kidney function (shown
by reduced estimated glomerular filtration rate (eGFR) or markers of kidney damage,
or both, for at least three months).^(4) The most common causes of CKD are diabetes,
hypertension and glomerulonephritis.^(9) CKD is associated with significant patient
morbidity and an increased risk of CV events, such as HF and premature death. In
its most severe form, known as ESKD, kidney damage and deterioration of kidney function
have progressed to the point where dialysis or kidney transplantation are required.
^(2) The majority of patients with CKD will die from CV causes before reaching ESKD.
^(10) Currently in Japan, more than 13 million people are living with CKD.^(11)

**DAPA-CKD**

DAPA-CKD was an international, multi-centre, randomised, double-blinded Phase III
trial in 4,304 patients designed to evaluate the efficacy of _Forxiga_ 10mg, compared
with placebo, in patients with CKD Stage 2-4 and elevated urinary albumin excretion,
with and without T2D. Forxiga was given once daily in addition to SoC. The primary
composite endpoint was worsening of renal function or risk of death (defined as 
a composite of an eGFR decline ≥50%, onset of ESKD or death from CV or renal cause).
The secondary endpoints included the time to first occurrence of the renal composite(
sustained ≥50% eGFR decline, ESKD or renal death), the composite of CV death or 
hospitalisation for HF (hHF), and death from any cause. The trial was conducted 
in 21 countries.^(1 )Detailed results from the trial were published in The New England
Journal of Medicine.^(1)

**_Forxiga_**

_Forxiga_ (dapagliflozin) is a first-in-class, oral, once-daily SGLT2 inhibitor.
Research has shown _Forxiga’s_ efficacy in preventing and delaying cardiorenal disease,
while also protecting the organs – important findings given the underlying links
between the heart, kidneys and pancreas.^(1,12,13) Damage to one of these organs
can cause the other organs to fail, contributing to leading causes of death worldwide,
including T2D, HF and CKD.^(14-16)

Forxiga is approved as an adjunct to diet and exercise to improve glycaemic control
in adults with T2D and in T2D to reduce the risk of hHF or CV death when added to
SoC based on the findings of the DECLARE-TIMI 58 Phase III CV outcomes trial.12 
Forxiga is also approved for the treatment of HFrEF and the treatment of CKD based
on the findings of the DAPA-HF and DAPA-CKD Phase III trials.1,13

DapaCare is a robust programme of clinical trials to evaluate the potential CV, 
renal and organ protection benefits of _Forxiga_. It includes more than 35 completed
and ongoing Phase IIb/III trials in more than 35,000 patients, as well as more than
2.5 million patient-years’ experience. _Forxiga_ is currently being tested in the
DELIVER Phase III trial to evaluate its efficacy in the treatment of patients with
HF with preserved ejection fraction with or without T2D and in the DAPA-MI Phase
III trial – a first of its kind, indication-seeking registry-based randomised controlled
trial in patients without T2D following an acute myocardial infarction (MI) or heart
attack.

> **Mene Pangalos, AstraZeneca Executive Vice President, BioPharmaceuticals R&D,
> said**: “This approval is an important step towards realising our ambition of 
> improving outcomes for patients with chronic kidney disease. While new medicines
> like _Forxiga_ advance the standard of care, we are also committed to the prevention
> and early detection of this often debilitating and life-threatening disease.”

Share on:
